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Summary – Several data are available about the implication of the dopaminergic system in the control of inward-
directed aggression. Previously, we suggested an involvement of D2-dopaminergic function in the expression of
suicidal behavior by demonstrating a smaller growth hormone (GH) response to apomorphine, a dopaminergic agonist,
in depressed patients with a history of suicide attempts in comparison to non-attempters. In the present study, in order
to test this hypothesis, GH responses to intravenous apomorphine were measured in non-depressed patients with a
history of suicide attempts. The study was performed in 17 non-depressed male patients with a score less than 12 on
the 17-item HAMD. The patients were subgrouped into suicide attempters (N = 7) and non-attempters (N = 10). Mean
GH peak responses to apomorphine differed significantly between suicide attempters and non-attempters: (mean ± SD)
for GH peak, 10.4 ± 8.2 ng/mL vs 27.3 ± 13.1 ng/ml, F = 9.0, P = 0.009. In conclusion, dopaminergic disturbances
seem to play a role in the biology of inward-directed aggression in non-depressed patients. © 2001 Éditions
scientifiques et médicales Elsevier SAS
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INTRODUCTION
An extended literature exists concerning the role of
serotonin in the biology of suicidal behavior. Few data
are available about the possible implication of the
dopaminergic system in the control of inward-directed
aggression. Postmortem studies have provided conflict-
ing results. Crow et al. [7] reported an increase in
homovanillic acid (HVA) concentrations in the hip-
pocampus but not the cortex of suicide victims. Ohm-
ori et al. [14] observed an increase in HVA levels in the
frontal cortex of individuals who committed suicide
compared to subjects who died due to physical illness.
In contrast, Beskow et al. [5] and Arranz et al. [4] did
not find any difference in HVA concentration at the
level of the cortex of suicided subjects. These results
have been confirmed in another study at the level of five
other cerebral areas (caudate, putamen, nucleus accum-
bens, amygdala, hippocampus) [6]. This study demon-
strated a decrease in dihydroxyphenylacetic acid
(DOPAC) concentrations in the caudate, putamen and
nucleus accumbens. The role of dopamine in suicidal
patients has also been evaluated in cerebrospinal fluid
(CSF) studies. Several studies have reported low HVA
levels in depressed patients with a history of suicide
attempts compared to controls [8]. Moreover, low CSF
HVA levels could be a more reliable index of suicidal
behavior than low CSF 5-indroxyindolacetic acid
(5-HIAA) [19].
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In 1992, we suggested an involvement of
D2-dopaminergic function in the expression of suicidal
behavior by demonstrating a smaller growth hormone
(GH) response to apomorphine, a dopaminergic ago-
nist, in depressed patients with a history of suicide
attempts in comparison to non-attempters [15].
Recently, we showed that depressed patients who later
died by suicide exhibited a significantly lower GH
response to apomorphine challenge than depressed
patients who never attempted suicide [18]. Neverthe-
less, this measure of impaired dopamine activity in
depressed patients could be related to the diagnosis of
depression or to certain aspects of symptomatology, in
particular motor retardation. In the present study, in
order to test this hypothesis, GH responses to subcuta-
neous injection of apomorphine were measured in non-
depressed patients with a history of suicide attempts.
METHODS
Subjects
The study was performed in 18 non-depressed male
inpatients with a score less than 12 on the 17-item
Hamilton depression scale (HAM-D) [10]. This score
was mainly due to aspecific symptoms such as psychic
and somatic anxiety, insomnia or somatic complaints.
All patients had a score less than 1 on the psychomotor
retardation item of the HAM-D scale. The DSM-III-R
clinical diagnoses of the patients [2] were personality
disorder (three cases); anxiety disorder (seven cases),
including five panic and two social phobic disorder
diagnoses; and adjustment disorder (eight cases). On
the basis of a clinical interview, we excluded patients
with another current DSM-III-R axis I disorder, and
more particularly an affective disorder. The patients
were subgrouped into suicide attempters (N = 7, per-
sonality disorder = 2, anxiety disorder = 3, adjustment
disorder = 2) and non-attempters (N = 11, personality
disorder = 1, anxiety disorder = 4, adjustment disor-
der = 5). The two groups did not differ in mean age or
weight. These patients were included in another study
[16]. The apomorphine test was performed after a
drug-free period of at least 2 weeks [17]. Moreover,
there was no significant difference in washout periods
between groups.
Past history of suicide attempt was based on inter-
views with patients and their family members. We only
included suicide attempts with a real intent to die as
described by patients. All patients were free of medical
illness as evidenced by history, medical examination,
electrocardiogram, chest x-ray, electroencephalogram,
and routine laboratory tests. Patients with a basal sys-
tolic blood pressure less than 100 mmHG were
excluded from the study. Moreover, in order to be
included, patients had to present a basal (t0) GH level
less than 5 ng/mL before the pharmacological chal-
lenge [3]. The exclusion of subjects with basal GH
values > 5 ng/mL was recommended by Laakman [11],
who demonstrated that ‘presimulator’ healthy volun-
teers responded significantly less to a noradrenergic
challenge than healthy volunteers with low basal values.
Finally, the protocol was approved by the Ethical Com-
mittee of the University of Liège Medical School, and
all patients were fully informed of the study and gave
their consent.
Neuroendocrine test procedure
The apomorphine test was performed in all subjects at
bedrest after an overnight fast. At 7 a.m, an indwelling
catheter was inserted in a forearm vein. Blood samples
of 10 mL were collected at –20, 0, +20, 40, 60 and
120 min after injection at 8 a.m. of apomorphine
0.5 mg diluted in saline to obtain 0.5 mL subcutane-
ously.
GH was measured with a double antibody radioim-
munoassay [9], with intra-assay and interassay coeffi-
cients of variation of, respectively, 13.3 ± 4.7% and
14.8 ± 9.6% and a detection limit of 0.2 ng/mL.
Data analysis
GH responses to apomorphine were measured by GH
peak values following injection. Analyses were per-
formed using absolute GH values as well as differences
related to basal (t0) levels (relative values). Since the
correlation between absolute and relative values were
very high (r > 0.98), only absolute values are reported
here. Moreover, since peak and area under the curve
values are generally highly correlated (r > 0.97), we
decided to choose GH peak values as the measure of
maximal hormonal response to apomorphine. The
responses of patients with and without a history of
suicide attempts were compared by analysis of covari-
ance (ANCOVA) for age.
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RESULTS
Mean GH peak responses to apomorphine differed
significantly between suicide attempters and non-
attempters (mean ± SD): for GH peak, 10.4 ± 8.2 ng/
mL vs 27.3 ± 13.1 ng/mL, F = 9.0, df = 3, 15,
P = 0.009.
DISCUSSION
The results of the present study tend to confirm a
specific role for D2-dopaminergic receptors in the biol-
ogy of inward-directed aggression in non-depressed
patients. Indeed, non-depressed patients with a history
of suicidal behavior exhibited a significantly lower GH
response to apomorphine challenge than patients who
had never attempted suicide. Therefore, a blunted GH
response to apomorphine could be considered as a
possible ‘biological marker’ of suicidal behavior.
These results are in agreement with several previous
studies assessing dopaminergic activity by measuring
CSF dopaminergic metabolites in suicide attempters.
Träskman et al. [23] found lower levels of CSF HVA in
patients with a history of either violent or nonviolent
suicide attempts than in controls. Montgomery and
Montgomery [13] and Agren [1] also showed a highly
significant relationship between low CSF HVA levels
and suicidal behavior, and a weaker correlation with
low CSF 5-HIAA levels. In a longitudinal study over a
period of 5 years, Roy et al. [20] observed that patients
who reattempted suicide during the follow-up had
lower CSF HVA levels compared to controls. The
predictive value of low CSF HVA concentrations has
been confirmed in another longitudinal study over a
period of 2 years [24]. More recently, Engtröm et al. [8]
confirmed the relationship between CSF HVA levels
and suicidality in a large sample of depressed patients.
Roy et al. [21] have also found that depressed patients
with a history of suicidal behavior exhibited smaller
urinary outputs of HVA, DOPAC and total body
output of dopamine than patients who never attempted
suicide. Moreover, Roy and Pollack [22] demonstrated
that urinary measures of the dopaminergic metabolites
could be a strong indicator of suicide risk. In contrast,
Mann and Malone [12] did not find any association
between CSF HVA levels and suicidality in depressed
suicide attempters with a high degree of lethality.
All CSF studies which tend to demonstrate an asso-
ciation between low HVA levels and suicidality have
been performed in suicide attempters with mood dis-
orders. Recently, Engstöm et al. [8] suggested that
discrepancies observed between several studies could be
explained by the clinical heterogeneity of suicide
attempters and that low HVA levels might be markers
of depression as such rather than a biological risk factor
of suicidal behavior. To our knowledge, our study is
one of the first to provide results suggesting a relation-
ship between dopaminergic function, and more specifi-
cally D2-receptors, and suicidal behavior in non-
depressed patients. Therefore, our results tend to suggest
that the association between dopamine and suicidality
could be observed in several diagnostic entities.
These results should be taken with caution due to the
small sample size. Moreover, a major limitation is that
the dopamine-mediated GH response to apomorphine
is occurring at the level of the hypothalamus. Regarding
the dopaminergic hypothesis of suicidal behavior, we
are particularly interested in dopaminergic function in
mesocortical and mesolimbic systems, and it is unclear
to what extent a hypothalamically-mediated endocrine
response is informative about these systems. Another
limitation is the lack of specific assessment of a possible
lifetime diagnosis of depression that could influence the
results.
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